Vaxinano
Developing life-changing vaccines and immunotherapies
Developing life-changing vaccines and immunotherapies
Vaxinano is a clinical-stage biotechnology company that is dedicated to the development of a new generation of nasally administered vaccines. The company's slogan, "Developing life-changing vaccines and immunotherapies," encapsulates their mission to combat infectious diseases and new pandemics in a more efficient and rapid manner. Founded in 2016, Vaxinano's approach is based on STELLAR-NP nanoparticles that provide a stable, adjuvant-free solution for an effective and long-lasting immune response against challenging pathogens such as parasites, viruses, and bacteria.
The company operates in the Biotechnology, Pharmaceutical, Logistics, and Delivery industries, reflecting its multidisciplinary approach to addressing healthcare challenges. Vaxinano's last reported investment was a non-equity assistance investment on 10 December 2016, with Eurasante listed as the investor. This signifies a strategic partnership and validation of Vaxinano's innovative vaccine technology. With its pioneering approach and support from investors, Vaxinano is positioned to make crucial advancements in vaccine development and contribute to global health security.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 | Eurasante | 10 Dec 2016 |
No recent news or press coverage available for Vaxinano.
We care about your data, and we'd love to use cookies make your experience better.
